Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JAFFER A AJANI and JEANNELYN SANTIANO ESTRELLA.
JAFFER A AJANI
Connection Strength
6.734
JEANNELYN SANTIANO ESTRELLA
  1. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer. 2024 Sep 17.
    View in: PubMed
    Score: 0.245
  2. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology. 2021; 99(10):659-664.
    View in: PubMed
    Score: 0.197
  3. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021 12; 70(12):2238-2248.
    View in: PubMed
    Score: 0.190
  4. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel). 2021 Jan 23; 13(3).
    View in: PubMed
    Score: 0.190
  5. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065.
    View in: PubMed
    Score: 0.189
  6. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888.
    View in: PubMed
    Score: 0.186
  7. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2021 Jan; 28(1):258-264.
    View in: PubMed
    Score: 0.182
  8. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today. 2020 Oct; 50(10):1223-1231.
    View in: PubMed
    Score: 0.181
  9. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021 01; 70(1):55-66.
    View in: PubMed
    Score: 0.181
  10. PPARd Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol Cancer Res. 2020 03; 18(3):390-402.
    View in: PubMed
    Score: 0.176
  11. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. 2019 Dec; 120(7):1137-1141.
    View in: PubMed
    Score: 0.173
  12. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
    View in: PubMed
    Score: 0.170
  13. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61.
    View in: PubMed
    Score: 0.152
  14. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40.
    View in: PubMed
    Score: 0.150
  15. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344.
    View in: PubMed
    Score: 0.150
  16. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Oct 06; 8(46):81430-81440.
    View in: PubMed
    Score: 0.149
  17. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.149
  18. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512.
    View in: PubMed
    Score: 0.148
  19. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301.
    View in: PubMed
    Score: 0.142
  20. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol. 2016 12; 17(12):1628-1629.
    View in: PubMed
    Score: 0.142
  21. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol. 2016 Aug; 7(4):499-505.
    View in: PubMed
    Score: 0.139
  22. Evolution of gastric surgery techniques and outcomes. Chin J Cancer. 2016 07 26; 35(1):69.
    View in: PubMed
    Score: 0.139
  23. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016; 91(1):55-60.
    View in: PubMed
    Score: 0.137
  24. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55.
    View in: PubMed
    Score: 0.135
  25. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016 Jan; 113(1):29-35.
    View in: PubMed
    Score: 0.133
  26. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10.
    View in: PubMed
    Score: 0.131
  27. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.
    View in: PubMed
    Score: 0.130
  28. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
    View in: PubMed
    Score: 0.127
  29. Molecular biomarkers in gastric cancer. J Natl Compr Canc Netw. 2015 Apr; 13(4):e19-29.
    View in: PubMed
    Score: 0.127
  30. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47.
    View in: PubMed
    Score: 0.123
  31. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79.
    View in: PubMed
    Score: 0.118
  32. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
    View in: PubMed
    Score: 0.105
  33. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20.
    View in: PubMed
    Score: 0.102
  34. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53.
    View in: PubMed
    Score: 0.098
  35. Phase 1 Trial of Total Neoadjuvant Therapy With Short-Course Chemoradiotherapy Followed by Chemotherapy for Patients With Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys. 2024 Sep 04.
    View in: PubMed
    Score: 0.061
  36. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825.
    View in: PubMed
    Score: 0.059
  37. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel). 2023 Oct 25; 15(21).
    View in: PubMed
    Score: 0.058
  38. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945.
    View in: PubMed
    Score: 0.056
  39. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw. 2021 Oct 22; 1-12.
    View in: PubMed
    Score: 0.050
  40. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery. 2021 10; 170(4):1231-1239.
    View in: PubMed
    Score: 0.049
  41. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6638-6648.
    View in: PubMed
    Score: 0.048
  42. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922.
    View in: PubMed
    Score: 0.047
  43. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151.
    View in: PubMed
    Score: 0.047
  44. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med. 2020 Oct 29; 9(11).
    View in: PubMed
    Score: 0.047
  45. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer. 2020 Sep; 20(3):313-327.
    View in: PubMed
    Score: 0.046
  46. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387.
    View in: PubMed
    Score: 0.046
  47. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
    View in: PubMed
    Score: 0.045
  48. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405.
    View in: PubMed
    Score: 0.045
  49. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811.
    View in: PubMed
    Score: 0.044
  50. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. 2020 05; 24(5):1018-1025.
    View in: PubMed
    Score: 0.044
  51. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26(11):3602-3610.
    View in: PubMed
    Score: 0.043
  52. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400.
    View in: PubMed
    Score: 0.041
  53. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
    View in: PubMed
    Score: 0.040
  54. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728.
    View in: PubMed
    Score: 0.040
  55. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018 Jul; 118(1):61-67.
    View in: PubMed
    Score: 0.040
  56. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29.
    View in: PubMed
    Score: 0.040
  57. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017.
    View in: PubMed
    Score: 0.039
  58. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013.
    View in: PubMed
    Score: 0.039
  59. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. 2018 08; 22(8):1325-1333.
    View in: PubMed
    Score: 0.039
  60. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018 Mar; 117(4):678-684.
    View in: PubMed
    Score: 0.038
  61. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. 2017 Oct; 21(10):1563-1570.
    View in: PubMed
    Score: 0.037
  62. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666.
    View in: PubMed
    Score: 0.037
  63. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
    View in: PubMed
    Score: 0.037
  64. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83.
    View in: PubMed
    Score: 0.037
  65. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017 Sep; 24(9):2679-2687.
    View in: PubMed
    Score: 0.036
  66. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol. 2017 Apr; 24(4):960-965.
    View in: PubMed
    Score: 0.035
  67. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol. 2016 Oct; 114(5):602-606.
    View in: PubMed
    Score: 0.035
  68. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016 12; 23(13):4332-4337.
    View in: PubMed
    Score: 0.035
  69. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016; 90(5):239-47.
    View in: PubMed
    Score: 0.034
  70. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. Carcinogenesis. 2014 Sep; 35(9):2031-8.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.